帕维拉治疗

最新新闻

• 评级变动
  Chardan Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240
  Market Newswire · 2026/5/21
• 评级变动
  Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250
  Market Newswire · 2026/6/24
• 评级变动
  Stephens Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $220
  Market Newswire · 2026/5/12
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)
  TipRanks · 2026/7/1
• 评级变动
  LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $225
  Market Newswire · 2026/7/22
• 评级变动
  A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $210 to $267
  Market Newswire · 2026/5/9
• Form 144 | Palvella Therapeutics(PVLA.US) Director Proposes to Sell 4.14 Million in Common Stocks
  Market Newswire · 2026/9/12
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA) and MBX Biosciences, Inc. (MBX)
  TipRanks · 2026/5/8
• 评级变动
  H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270
  Market Newswire · 2026/8/6
• Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $240
  Market Newswire · 2026/9/21
• 评级变动
  Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207
  Market Newswire · 2026/8/5
• BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215
  Market Newswire · 2026/7/22
• 评级变动
  A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $210 to $270
  Market Newswire · 2026/5/22
• 评级变动
  A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $267
  Market Newswire · 2026/8/5
• Palvella Therapeutics(PVLA.US) Director Sells US$4.17 Million in Common Stock
  Market Newswire · 2026/9/16
• 评级变动
  CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227
  Market Newswire · 2026/6/25
• 评级变动
  Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210
  Market Newswire · 2026/8/5
• Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240
  Market Newswire · 2026/9/10
• 评级变动
  Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205
  Market Newswire · 2026/6/22
• 评级变动
  TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267
  Market Newswire · 2026/7/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。